Published • loading... • Updated
If Congress starts reviewing licensing deals, diligence gets a documentation problem
The bill would require more disclosures on Chinese biotech transactions and expand review of deals that could affect U.S. national security.
- Congress is weighing legislation to amend the COINS Act by adding biotechnology as a covered sector, which would expand federal review of cross-border licensing deals with Chinese companies.
- Cross-Border licensing deals between U.S. and Chinese biopharma companies grew by $131 billion from 2020 to 2025, prompting lawmakers to propose stricter oversight of transactions previously outside national security review frameworks.
- Kivo identified redacted licensing diligence files revealing deal structures, while reporting cites missing records and stressed processes that have raised regulatory concerns about transaction documentation completeness.
- Industry trade groups and corporate counsel plan to challenge broad congressional subpoenas, as firms prepare legal pushback that could increase compliance costs for licensing counterparties immediately.
- Existing security review frameworks allow committees to leverage established protocols rather than drafting new discovery rules, positioning Treasury to scrutinize sensitive commercial biotechnology deals under a one-year implementation timeline.
Insights by Ground AI
60 Articles
60 Articles
If Congress starts reviewing licensing deals, diligence gets a documentation problem - The Mexico Ledger
Historically, national security reviews were not a topic of conversation in biotech licensing deals. Things are changing.The bipartisan Biotech Investment National Security Act of 2026 would amend the COINS Act by adding biotechnology as a covered sector, expand reviewable transactions to include licensing deals, and give the U.S. Treasury a year to write rules for implementation. This change follows two recent multi-billion-dollar licensing dea…
thepampanews.com+58 Reposted by 58 other sources
If Congress starts reviewing licensing deals, diligence gets a documentation problem
Kivo reports that the Biotech Investment National Security Act of 2026 will expand U.S. licensing deal reviews to include biotechnology, creating new documentation requirements.
·Pampa, United States
Read Full ArticleCoverage Details
Total News Sources60
Leaning Left5Leaning Right7Center46Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
79% Center
C 79%
12%
Factuality
To view factuality data please Upgrade to Premium
